O4‐06‐07: Imaging and cerebrospinal fluid biomarker results of a phase II dose‐ranging study of ELND005 (Scyllo‐inositol) in mild‐to‐moderate Alzheimer's disease
Porsteinsson A, Sperling R, Salloway S, Keren R, van Dyck C, Tariot P, Arnold D, Crans G, Hernandez R, Liang E, Bairu M, Cedarbaum J, Pastrak A, Abushakra S. O4‐06‐07: Imaging and cerebrospinal fluid biomarker results of a phase II dose‐ranging study of ELND005 (Scyllo‐inositol) in mild‐to‐moderate Alzheimer's disease. Alzheimer's & Dementia 2011, 7: s695-s695. DOI: 10.1016/j.jalz.2011.05.2010.Peer-Reviewed Original ResearchP2‐499: Safety and efficacy results of a phase II randomized, placebo‐controlled, dose‐ranging study of elnd005 (scyllo‐inositol) in mild‐to‐moderate Alzheimer's disease
Salloway S, Porsteinsson A, Sperling R, Keren R, van Dyck C, Tariot P, Gilman S, Crans G, Hernandez R, Quinn G, Bairu M, Cedarbaum J, Pastrak A, Abushakra S. P2‐499: Safety and efficacy results of a phase II randomized, placebo‐controlled, dose‐ranging study of elnd005 (scyllo‐inositol) in mild‐to‐moderate Alzheimer's disease. Alzheimer's & Dementia 2011, 7: s472-s472. DOI: 10.1016/j.jalz.2011.05.1371.Peer-Reviewed Original Research